Your session is about to expire
← Back to Search
PF-06700841 30 mg for Lupus
Study Summary
This trial is assessing the efficacy of PF-06700841 in treating moderate to severe active SLE in patients who have failed to respond to standard of care.
- Lupus
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 194 Patients • NCT04092452Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have moderate to severe active Lupus.You have active chronic pain, including fibromyalgia and myofascial pain syndrome.You have a mental health condition that includes thoughts or actions of hurting yourself.You have a serious and active case of lupus that affects your brain and nervous system.
- Group 1: PF-06700841 45 mg
- Group 2: PF-06700841 30 mg
- Group 3: Placebo
- Group 4: PF-06700841 15 mg
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there any capacity for participants to join this research?
"This clinical trial is not actively enrolling participants at this time. Initially posted on April 18th 2019 and last modified November 17th 2022, it has since been closed for new patients. For those searching for alternative studies related to lupus erythematosus, systemic there are 124 trials open presently; additionally 3 clinical trails concerning PF-06700841 30 mg are also recruiting."
How many sites are administering this research endeavor?
"The trial is accepting participants from 7 different sites, located in Toronto, Bethlehem and Syracuse among other cities. It is recommended that the closest location to you be selected so as to reduce the transit burden associated with participation."
Has PF-06700841 30 mg been tested for efficacy in any prior research experiments?
"Presently, there are 3 clinical trials for PF-06700841 30 mg in progress with none of those being Phase 3. Whilst the majority of testing locations are situated Sosnowiec, Idaho, a total 422 sites have been enlisted to participate."
What possible side effects can be experienced with a dose of PF-06700841 30 mg?
"Based on available data, the safety rating of PF-06700841 30 mg is assessed as a 2. This drug has been tested to some degree for its security profile but there are no clinical studies that have proven its efficacy yet."
For what types of individuals is this research trial appropriate?
"Prospective patients of this trial must meet the inclusion criteria, which is lupus erythematosus systemic and an age range between 18 to 75. A total of 346 individuals will be enrolled in the experiment."
How many individuals is this experiment encompassing?
"Unfortunately, this clinical trial is not currently enrolling patients. It was initially posted on April 18th 2019 and most recently updated November 17th 2022. However, if you are in search of other studies, there are 124 trials looking for participants with lupus erythematosus systemic and 3 separate ones searching for volunteers to test PF-06700841 30 mg."
Does this trial utilize any unique methods or approaches?
"Presently, 3 studies using PF-06700841 30 mg are in progress across 143 cities and 39 countries. The initial investigation on this pharmaceutical was conducted by Pfizer in 2018 with 246 participants completing Phase 2 clinical trials. Since then, 18336 trials have been finalized."
Are participants of an advanced age eligible to join this clinical examination?
"This medical study is seeking participants who are within the age range of 18 to 75 years old."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger